Mesenchymal stromal cells impair the differentiation of CD14++ CD16- CD64+ classical monocytes into CD14++ CD16+ CD64++ activate monocytes

Cytotherapy

Volumn 14, Issue 1, 2012, Pages 12-25

  Rocher, Bárbara Du ^a,b   Mencalha, Andre Luiz ^a,b   Gomes, Bernadete Evangelho ^a   Abdelhay, Eliana ^a,b  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

immunosuppression; mesenchymal stromal cells; monocyte subsets

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD64 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN P 15095; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; ARTICLE; CELL CONTACT; CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; CELL INTERACTION; CELL TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MESENCHYMAL STROMAL CELL; MESENCHYMAL STROMAL CELL TRANSPLANTATION; MESENCHYME CELL; MIXED LYMPHOCYTE REACTION; MONOCYTE; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; STROMA CELL;

EID: 83755229588     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.594792     Document Type: Article

References (58)

1. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6: 230-47.
2. Da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119:2204-13. (Pubitemid 43960310)
3. Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev. 2006;20:161-71.
4. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-7. (Pubitemid 29282067)
5. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726-36.
6. Sch äf er R, Northoff H. Cardioprotection and cardiac regeneration by mesenchymal stem cells. Panminerva Med. 2008; 50:31-9.
7. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28:1099-106.
8. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or nonspecifi c mitogenic stimuli. Blood. 2002;99:3838-43. (Pubitemid 34534559)
9. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42-8. (Pubitemid 34059216)
10. Yang M, Wei X, Li J, Heine LA, Rosenwasser R, Iacovitti L. Changes in host blood factors and brain glia accompanying the functional recovery after systemic administration of bone marrow stem cells in ischemic stroke rats. Cell Transplant. 2010;19:1073-84.
11. Zhao MZ, Nonoguchi N, Ikeda N, Watanable T, Furutama D, Miyazawa D, et al. Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J Cereb Blood Flow Metab. 2006;26:1176-88. (Pubitemid 44268180)
12. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and cultureexpanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol. 2000;18:307-16. (Pubitemid 30056419)
13. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, et al. Cotransplantation of ex-vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood. 2007;110:2764-7. (Pubitemid 47523204)
14. Macmillan ML, Blazar BR, DeFor TE, Wagner JE. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phasei- II clinical trial. Bone Marrow Transplant. 2009;43:447-54.
15. Le Blanc K, Rasmusson I, Sundberg B, G öt herströ m C, Hassan M, Uzunel M, et al. Treatment of severe acute graftversus- host disease with third party haploidentical mesenchymal stem cells. Lance. 2004;363:1439-41. (Pubitemid 38586721)
16. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet. 2008;371:1579-86. (Pubitemid 351626841)
17. Zhang W, Ge W, Li C, You S, Liao L, Han Q, et al. E ffects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004;13:263-71. (Pubitemid 38738368)
18. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al. Human mesenchymal stem cells alter antigenpresenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105:2214-9. (Pubitemid 40731815)
19. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005; 105:4120-6. (Pubitemid 40656164)
20. 34+ -derived and monocyte-derived dendritic cells. J Immunol. 2006;177:2080-7. (Pubitemid 44200965)
21. Jung YJ, Ju SY, Yoo ES, Cho SJ, Cho KA, Woo SY, et al. MSC-DC interaction: MSC inhibit maturation and migration of BM-derived DC. Cytotherapy. 2007;9:451-8. (Pubitemid 47386682)
22. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6- dependent mechanism. Stem Cells. 2007;25:2025-32. (Pubitemid 47258180)
23. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 2007;83:71-6. (Pubitemid 46104974)
24. English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett. 2008:115:50-8. (Pubitemid 350298590)
25. 34+ hemohemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol. 2008;180:1598-608.
26. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood. 2009; 113:6576-83.
27. Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15:42-9.
28. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages. Exp Hematol. 2009;37:1445-53.
29. Maggini J, Mirkin G, Bognanni I, Holmberg J, PiazzónIM, Nepomnaschy I, et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory- like profi le. PLoS ONE. 2010;5:1-13.
30. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. at Rev Immunol. 2005;5:953-64. (Pubitemid 41746764)
31. Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol. 2001;69:11-20. (Pubitemid 32095112)
32. 16+ subpopulation. Immunol Today. 1996;17:424-8. (Pubitemid 26278368)
33. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: Development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669-92.
34. 16+ monocytes are main producers of IL-10. Scand J Immunol. 2007;67:152-9.
35. 16+ blood monocytes: Their role in infection and infl ammation. J Leukoc Biol. 2007;81:584-92. (Pubitemid 46393535)
36. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiol. 2006;211:609-18.
37. Yrlid U, Jenkins CD, MacPherson GG. Relationships between distinct blood monocyte subsets and migrating intestinal lymph dendritic cells in vivo under steady-state conditions. J Immunol. 2006;176:4155-62. (Pubitemid 44264395)
38. 16+ and CD16 - monocyte subsets. BMC Genomics. 2009;10:1-19.
39. 4+ T cells. Int Immunol. 2001;13:1571-81. (Pubitemid 33133884)
40. 103+ and CD103 - pulmonary dendritic cell populations. J Immunol. 2008;180:3019-27.
41. 16+ Fc RIII subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med. 2002;196:517-27.
42. 16+ blood monocytes. Eur J Immunol. 2001;31:48-56.
43. Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versusleukemia. Blood. 2007;110:9-17. (Pubitemid 47026813)
44. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defi ning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7. (Pubitemid 44269669)
45. Lazzarotto-Silva C, Binato R, Rocher BD, Costa JA, Pizzatti L, Bouzas LF, et al. Similar proteomic profi les of human mesenchymal stromal cells from different donors. Cytotherapy. 2009;11:268-77.
46. Dragowska WH, Lopes de Menezes DE, Sartor J, Mayer LD. Quantitative fl uorescence cytometric analysis of Bcl-2 levels in tumor cells exhibiting a wide range of inherent Bcl-2 protein expression: Correlation with Western blot analysis. Cytometry. 2000;40:346-52. (Pubitemid 30643193)
47. Storie I, Sawle A, Goodfellow K, Whitby L, Granger V, Reilly JT, et al. Flow rate calibration I: A novel approach for performing absolute cell counts. Cytometry B. 2003;55:1-7. (Pubitemid 38295402)
48. Wan CP, Park CS, Lau BHS. A rapid and simple microfl uorometric phagocytosis assay. J Immunol Methods. 1993; 162:1-7.
49. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386-98. (Pubitemid 44464808)
50. Jones S, Horwood N, Cope A, Dazzi F. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol. 2007;179: 2824-31.
51. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38:1745-55.
52. 34+ hematopoietic progenitors. J Leukoc Biol. 2007;82: 594-602.
53. Cutler AJ, Limbani V, Girdlestone J, Navarrete CV. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J Immunol. 2010; 185:6617-23.
54. 14+ monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells. Exp Cell Res. 2010;316: 2414-23.
55. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol. 2002; 23:144-50. (Pubitemid 34178297)
56. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharm Rev. 2004;56:387-437. (Pubitemid 39096597)
57. 12,14 -prostaglandin J2 inhibits multiple steps in the NF-kB signaling pathway. Proc Natl Acad Sci. 2000;97:4844-9. (Pubitemid 30238645)
58. Scher JU, Pillinger MH. 15d-PGJ2: The anti-infl amatory prostaglandin? Clin Immunol. 2005;114:100-9.